国产人人色I色婷婷综合久久中文字幕雪峰I奇米色777欧美一区二区I久热久热aV爽青青在线I国产av喷水I国产伦精品一区二区三区免.费I高潮av在线Iww欧美一级I91天天看I黄a在线91I九一无码中文字幕久久无码色…I丰满国产精品视频二区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / China Development Forum 2026

Novartis announces further China investment

By Li Jing | chinadaily.com.cn | Updated: 2026-03-23 14:36
Share
Share - WeChat

Swiss pharmaceutical company Novartis is to expand its research and development, manufacturing capacity and operations footprint in China, with planned investment of more than 3.3 billion yuan ($460 million), a gathering in Beijing has heard.

The announcement came as the China Development Forum annual meeting opened in Beijing on Sunday, with Vas Narasimhan, the chief executive officer of Novartis, attending for the eighth time.

"China is critical to Novartis' long-term development and innovation," Narasimhan said, adding that the Basel-based company will continue to bring innovative medicines to Chinese patients and aims to be a trusted healthcare partner in the country.

Novartis said China has become its second-largest market globally, and the company plans to launch a large-scale investment and expansion program this year to strengthen innovation and manufacturing capacity in the country.

Its Changping plant in Beijing, established in 1987, is a major production site in the company's global manufacturing network. The facility has started a new round of expansion and upgrade projects, with planned investment of about 1.5 billion yuan to build new facilities and introduce new sterile preparation, liquid filling and packaging technologies.

The company's Shanghai campus, which serves as Novartis' China headquarters, will mark its 10th year of operations this year. Novartis plans to jointly invest 1.8 billion yuan with partners to launch the second phase of the project.

Novartis pioneers radioligand therapy, which treats certain cancers, with its targeted PSMA radioligand therapy receiving approval in China for two indications in November last year.

Major construction is complete on the company's radioligand manufacturing facility in Haiyan county, Zhejiang province - the first of its kind in China. Once the site, which has seen an investment of 600 million yuan, reaches full production capacity, it will help reduce waiting time for Chinese patients seeking radioligand therapy.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE